18 december 2019
18 december 2019

Xenikos announces first patient receives T-Guard® for steroid-refractory acute GVHD in pivotal U.S.-based Phase 3 trial

Do you like it?
Read more
3 december 2019
3 december 2019

Xenikos presents promising new data from expanded access program (EAP) using T-Guard® to treat steroid-refractory acute GVHD at ASH Annual Meeting

Do you like it?
Read more
2 december 2019
2 december 2019

Xenikos appoints Stanley Musial as Chief Financial Officer and Chief Business Officer

Do you like it?
Read more
Load more